Efficacy of recombinant VAXXITEK HVT-IBDv vaccine against very virulent Infectious bursal disease virus (vvIBDv) challenge in layer chicks: A pilot study


Keywords:
poultry IBDv intermediate vaccines recombinant vaccines challenge
M. DAČIĆ
R. RESANOVIC
Z. RASIC
M. VALCIC
A. MILOVANOVIC
M. VELHNER
Abstract

The infectious bursal disease virus (IBDv) is widespread in poultry flocks all around the world. Various biotypes have emerged and because of that, adequate management practices and vaccination of chicks are of paramount importance for the protection against field strains. One day old Lohmann Brown chicks were vaccinated with intermediate vaccines and the recombinant VAXXITEK HVT-IBDv vaccine formulation, and challenged at 48 days of life with the very virulent IBDv (vvIBDv) strain CH/99. The best protection (100%) was achieved with the recombinant vaccine administered by the subcutaneous or intramuscular route at a day old, while intermediate and intermediate plus vaccines protected 80% of birds from clinical symptoms. The highest bursa body ratio (5.33, 3.50 and 4.12) was accomplished in non- vaccinated and non-challenged birds and birds vaccinated with the VAXXITEK HVT-IBDv vaccine. The recombinant VAXXITEK HVT-IBDv vaccine has provided protection for commercial chicks against challenge with the vvIBDv strain in this experiment. Under field conditions, additional vaccination is possibly needed with supplementary application of live attenuated vaccines. However, the recombinant vector vaccines are providing significant aid against clinical signs and immunosupression caused by the vvIBDv.

Article Details
  • Section
  • Research Articles
Downloads
Download data is not yet available.
References
Aly R, El-Sanousi A, El-Mahdy S (2012) Laboratory evaluation of live recombinant HVT-IBD vaccine. Report and Opinion 4:1-11. 2012. http://www.sciencepub.net/report
Aliyu HB, Sa’idu L, Jamilu A, Andamin AD, Akpavie SO (2016) Outbreaks of virulent infectious bursal disease in flocks of battery cage brooding system of commercial chickens. J Vet Med Volume 2016 (2016), Article ID 8182160, 7 pages. http://dx.doi.org/10.1155/2016/8182160
Bayliss CD, Spies U, Shaw K, Peters RW, Papageorgiou A, Müller H, Bousnell MEG (1990) A comparison of the sequences of segment A of four infectous bursal disease virus strains and identification of a variable region in VP2. J Gen Virol 71:1303-1312.
Bublot M, Pritchard N, Le Gros F-X, Goutebroze S (2007) Use of a vectored vaccine against infectious bursal disease of chickens in the face of high-titred maternally derived antibody. J Comp Pathol, 137 S1:S81-S84.
Chettle N, Stuart JC, Wyeth PJ (1989) Outbreak of virulent infectious bursal disease virus in East Anglia. Vet Rec 125:271-272.
Darteil R, Bublot M, Laplace E, Bouquet J-F, Audonnet J-C, Rivière M (1995) Herpesvirus of turkey recombinant viruses expressing infectious bursal disease virus (IBDV) VP2 immunogen induce protection against an IBDV virulent challenge in chickens. Virology 211:481-490.
Directive 2010/63/EU of the European Parliament and of the Council on the protection of animals used for scientific purposes. Dobrosavljević I, Vidanović D, Velhner M, Miljković B, Lako B (2014) Simultaneous detection of vaccinal and field infectious bursal disease viruses in layer chickens challenged with a very virulent strain after vaccination. Acta Vet Hung 62:264-273.
Gelb J Jr, Jackwood DJ, Brannick EM, Ladman BS (2016) Efficacy of recombinant HVT-IBDV vaccines administered to broiler chicks from a single breeder flock at 30 and 60 weeks of age. Avian Dis 60:603-612.
Gimeno IM (2008) Marek’s disease vaccines: A solution for today but a worry for tomorrow? Vaccine 26 S3:C31-C41.
Hein RG, (2011) Issues of the poultry recombinant viral vector vaccines which may cause an effect on the Economic benefits of those vaccines. XVII World Veterinary Poultry Association (WVPA) Congress in Cancún, Mexico, August 14-18.
Le Gros FX, Dancer A, Giacomini C, Pizzoni L, Bublot M, Graziani M, Prandini F (2009) Field efficacy trial of a novel HVT-IBD vector vaccine for 1-day-old broilers. Vaccine 27:592-596.
Lemiere S, Gauthier J-C, Kodjo A, Vinit L, Delvecchio A, Prandini F (2013) Evaluation of the protection against infectious busal disease (IBD) challenge in progeny born to parents having received a vaccination program using a Herpesvirus of turkey-infectious bursal disease (HVT-IBD) vector vaccine. World J Vaccine 3:46-51.
Le Nouën C, Toquin D, Müller H, Raue R, Kean KM, Langlois P, Cherbonnel M, Eterradossi N (2012) Different domains of the RNA polymerase of infectious bursal disease virus contribute to virulence. PLoS One 7, e28064, doi:10.1371/journal.pone.0028064
Massi P, Tosi G, Fiorentini L. (2008) Experimental challenge trial with a “very virulent” strains of infectious bursal disease virus (vvIBDV) in commercial pullets vaccinated with an IBD vectored vaccine or with three different modified live vaccines. By courtesy of MERIAl, Zootecnica novembar 2008.
Müller H, Scholtissek C, Becht H (1979) The genome of infectious bursal disease virus consists of two segments of double-stranded RNA. J Virol 31:584-589.
Müller H, Mundt E, Eterradossi N, Islam MR (2012) Current status of vaccines against infectious bursal disease. Avian Path 41:133-139.
Mundt E, Beyer J, Müller H (1995) Identification of a novel viral protein in infectious bursal disease virus-infected cells. J Gen Virol 76:437-443.
Perozo F, Villegas AP, Fernandez R, Cruz J, Pritchard N (2009) Efficacy of single dose recombinant herpesvirus of turkey infectious bursal disease (IBDV) vaccination against a variant strain. Avian Dis 53:624-628.
Prandini F, Simon B, Jung A, Pöppel M, Lemiere S, Rautenschlein S (2016) Comparison of infectious bursal disease live vaccines and a HVT-IBD vector vaccine and their effects on the immune system of commercial layer pullets. Avian Path 45:114-125.
Rashid MH, Luo H, Akhter J, Islam MT, Islam MR, Rahman MM, Cao Y, Xue C (2013) Protection effect of VAXXITEK HVT+IBD vaccine against infectious bursal disease in broiler chickens. Progress Agric 24:69-78
Rautenschlein S, Kraemer Ch, Vanmarcke J, Montiel E (2005) Protective efficacy of intermediate and intermediate plus infectious bursal disease virus (BDV) vaccines against very virulent IBDV in commercial broilers. Avian Dis 49:231-237.
Roh JH, Kang M, Wei B, Yoon RH, Seo HS, Bahng JY, Kwon JT, Cha SY, Jang HK (2016) Efficacy of HVT-IBD vector vaccine compared to attenuated live vaccine using in-ovo vaccination against a Korean very virulent IBDV in commercial broiler chickens. Poultry Sci 95:1020-1024.
Sharma JM, Dohms JE, Metz AL (1989) Comparative pathogenesis of serotype 1 and variant serotype 1 isolates of infectious bursal disease and their effect on humoral and cellular immune competence of specific- pathogen-free chickens. Avian Dis 33:112-124.
Tsukamoto K, Saito S, Saeki S, Sato T, Tanimura N, Isobe T, Mase M, Imada T, Yuasa N, Yamaguchi S (2002) Complete, long-lasting protection against lethal infectious bursal disease virus challenge by a single vaccination with an avian herpesvirus vector expressing VP2 antigens. J Virol 76:5637-5645.
Zorman-Rojs O, Krapež U, Slavec B, Juršić-Cizerl R, Poljanec T (2011) Field efficacy of different vaccines against infectious bursal disease in broiler flocks. Acta Vet Hung 59:385-398.
Most read articles by the same author(s)